Fluent

Fluent FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Fluent (TIUM.U.CN) as of Nov 5, 2026 is -53.26 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -32.79 % — a change of 62.45% (lower).

FCF Conversion

-53.26 %

YoY

62.45%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Fluent is 2023 -53.26 % . FCF Conversion Rate (FCF/EBITDA) of Fluent was 2022 -32.79 % . It decreases by 62.45% lower compared to the previous year.

The Fluent FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
56.39 USD
Jan 1, 2020
-7.91 USD
Jan 1, 2021
138.69 USD
Jan 1, 2022
-32.79 USD
Jan 1, 2023
-53.26 USD
The Fluent FCF Conversion history
YEARFCF ConversionYoY
-53.26 %+62.45%
-32.79 %-123.64%
138.69 %-1,853.68%
-7.91 %-114.02%
56.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluent Stock analysis

What does Fluent do? Fluent Corp operates under the private label Fluent, selling medical cannabis products in Florida, Texas, and Pennsylvania. The company's products include oral drops, capsules, suppositories, topicals, syringes, dried flower, pre-rolls, cartridges, edibles, and accessories. Subsidiaries such as Cansortium Holdings LLC and Cansortium Florida, LLC handle production and sales, while Fluent Servicing, LLC manages servicing aspects. The company's revenue comes from direct sales of medical cannabis products through its licensed operations in multiple states. Fluent Corp's target customers are patients seeking medical cannabis treatments, with products tailored to various consumption methods. The company leverages its subsidiaries to maintain compliance and expand its market reach across different states. Sales are conducted through licensed dispensaries and medical cannabis programs, focusing on the healthcare segment of the cannabis industry. The business model relies on the production and sale of medical cannabis under the private label Fluent, utilizing subsidiaries to manage state-specific operations. Products are distributed through established medical cannabis channels, with no mention of additional revenue streams beyond product sales. The company's focus remains on the medical cannabis market, serving patients in Florida, Texas, and Pennsylvania. Fluent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluent stock

FCF Conversion Rate (FCF/EBITDA) of Fluent is -53.26 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of Fluent changed from -32.79 % to -53.26 %, representing a 62.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Fluent since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Fluent with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Fluent

All Key Metrics — Fluent